Hyloris Pharmaceuticals SA

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 11:35:11 2024-04-24 am EDT			5-day change	1st Jan Change
11.95 ^EUR	+2.14%		-0.42%	-6.27%

Mar. 14	Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	CI
Mar. 14	Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024

Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Half Year Ended June 30, 2020

August 06, 2020 at 01:00 am EDT

Hyloris Pharmaceuticals SA reported consolidated earnings results for the half year ended June 30, 2020. For the period, revenue was €82,000 against €75,000 a year ago. Operating loss was €3,633,000 against €1,026,000 a year ago. Loss of the period was €3,742,000 against €1,314,000 a year ago. Basic and diluted loss per share was €0.21 against €0.07 a year ago.

Latest news about Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024	Mar. 14	CI
Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024	Mar. 14
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada	Feb. 28	MT
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse	Feb. 15	MT
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	Feb. 14	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	Feb. 06	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	Feb. 05	MT
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis	Jan. 30	CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	Jan. 18	MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus	Jan. 18	CI
Hyloris Pharmaceuticals Wins US FDA's Orphan Drug Designation for Leukemia Treatment	Jan. 17	MT
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate	Dec. 21	MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals	Dec. 21	CI
Hyloris Pharmaceuticals Partner Gets US FDA Nod for Warts Gel	Dec. 04	MT
Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada	23-10-26	CI
Hyloris Pharmaceuticals’ Pain Relief Drug Gets US FDA Approval; Shares Jump	23-10-18	MT
Hyloris Pharma wins US FDA approval for pain treatment	23-10-18	RE
Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV	23-10-18	CI
Transcript : Hyloris Pharmaceuticals SA, H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-06	CI
Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-JUN-2023.	23-06-25	CI
Hyloris Pharmaceuticals Wins EUR1 Million Grant to Develop Idiopathic Rhinitis Treatment	23-06-09	MT
Hyloris Partner Submits Additional Data to US FDA for Non-opioid Pain Treatment	23-04-18	MT
Transcript : Hyloris Pharmaceuticals SA, 2022 Earnings Call, Mar 16, 2023	23-03-16

Chart Hyloris Pharmaceuticals SA

Duration

Period

More charts

Company Profile

Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.

Sector

Pharmaceuticals

Calendar

2024-06-03 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Hyloris Pharmaceuticals SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.95 EUR

Average target price

21.55 EUR

Spread / Average Target

+80.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HYLORIS PHARMACEUTICALS SA	-6.27%	351M
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals